Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurex Corporation -- Ignore unavailable to you. Want to Upgrade?

To: cur who wrote (420)	3/13/1998 11:34:00 PM
From: Tagore	Respond to of 449

Preliminary results of first 230 patients in head trauma will be reported in the 4th quarter. More importantly, Warner Lambert had another program in this area and has stopped it (apparently because this program is going better) and the safety of Ziconotide is "looking good." Phase II trials on acute pain (36 patients -epidaural) will report in 3rd or 4th quarter and, if ok, pivotal trial will commence by end of year. We should also hear about partnerships for chronic pain in Europe and patch for renal therapy this year.